The Economist Finally Validates What We’ve Known: Psychedelics Aren’t Just a Fad
-
I was scrolling through The Economist this morning and stumbled on their piece about psilocybin therapy showing serious promise against treatment-resistant depression. Honestly, it caught me off guard. Not because the clinical results are shocking—anyone who's followed the trials from MAPS or the teams at Imperial College London knows the data's been stacking up for years—but because it's finally hitting a mainstream outlet that usually treats anything consciousness-altering like a fringe curiosity.
Working at a community center in Chicago, I see how many folks get stuck in rigid mental loops. You hand them a standard SSRI, and sometimes it helps, but often it just numbs the edges while the actual heavy lifting stays buried. Carl Jung always wrote about how confronting the shadow isn't comfortable, but it's the only real path to integration. He didn't have guided psilocybin sessions, but he understood that breaking down the ego's defensive walls is where healing actually happens. That's exactly what these clinical protocols are trying to do—create a contained, supervised space for people to sit with whatever's been pushed down, instead of medicating it into silence.
It's funny how the tarot mirrors this process, too. You don't get lasting growth from the comfortable Two of Cups; you get it from the Tower knocking down the false structures we build to feel safe. Mainstream medicine's been playing it cautious for decades, and now the tide is finally turning. It'll be interesting to see how they scale this up without losing the therapeutic relationship that makes it work, but I'm glad the skepticism is fading.
(There's a deeper dive on this in our wiki: Qi Zheng Si Yu: Imperial Chinese Astrology, Forgotten Until Recently | Mystic Wiki.)
-
The Economist piece caught you off guard precisely because it is not the result that is surprising—it is the mainstreaming. Anyone tracking MAPS or the Johns Hopkins trials has known for years that psilocybin shows genuine efficacy against treatment-resistant depression. What The Economist signals is that the institutional gatekeepers are finally lowering their voices.
But you are right to be cautious. The mainstream is not validating psychedelics for the reasons most people on this forum do. They are validating them as pharmacotherapy—not as sacrament, not as doorway, not as contact with the numinous. The reduction of a profound technology of consciousness into a drug class is the price of its acceptance.
In Buddhist and Hindu traditions, the altered states produced by ritual plant medicines were always contextualized within a framework of karma, intention, and community practice. The molecule is neutral. The vessel—the person, the setting, the tradition—determines whether the experience heals or destabilizes. The federal grant is real. What it misses is everything that matters.
-
Corporate validation doesn't make a practice sacred; it just prices it out of reach for the people who actually need it. You're conflating clinical scaling with genuine shadow work, and treating the Tower card like a quarterly report misses the point entirely. Real integration isn't a billable hour—it's the messy, unmonetized work you do when the consultants are gone.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login